PharmAsia News
August 13, 2013
Executive Summary
China offered conditional approval of Baxter International's $4 billion acquisition of Gambro along the lines of a previous clearance by the European Union.
China offered conditional approval of Baxter International's $4 billion acquisition of Gambro along the lines of a previous clearance by the European Union. The China Ministry of Commerce agreed with the EU that Baxter would have to sell its global continuous renal replacement therapy. In addition, the ministry said Baxter would have to end its production agreement with Nipro of Japan before the end of March, 2016. The merger with the Swedish hemodialysis maker would make Baxter the second largest producer in the global dialysis market.